DS with menin inhibitors is a class effect with overall rates of about 28% with revumenib in the AUGMENT-101 study (16% grade 3) and 21% all-grade DS with ziftomenib in the KOMET study including phase 1a and 1b (n = 83), of which 14% were grade 3. This evidence concerns the gene MEN1 and Dravet syndrome.